No Data
No Data
Beijing centergate technologies (000931.SZ): Subsidiary company Beijing Huasu has obtained an invention patent certificate.
On September 27, Gelonghui announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd., under Beijing Centergate Technologies (000931.SZ), recently obtained a patent for invention issued by the National Intellectual Property Administration, with the invention named as a bisoprolol formulation and its preparation method.
Beijing Centergate Technologies (000931.SZ), a subsidiary of the company, plans to acquire 51% equity of Guomei Internet Hospital for 0 yuan to expand its retirement medical business.
beijing centergate technologies (000931.SZ) announcement, the company's wholly-owned subsidiary beijing huasutang csi old-age industry investment co., ltd. (abbreviated...
Beijing Centergate Technologies (000931.SZ): The consistency evaluation application for Naxitone Hydrochloride Tablets (specification: 50mg) has been accepted.
beijing centergate technologies (000931.SZ) issued an announcement, its subsidiary company beijing huasu pharmaceutical co., ltd. (hereinafter referred...
Beijing Centergate Technologies (000931.SZ): Signed a global strategic cooperation agreement with Hailai Technology.
Beijing Centergate Technologies (000931.SZ) announced that to leverage their respective strengths, promote coordinated development, and jointly support the development of pharmaceuticals in China, the company has signed a strategic cooperation framework agreement with HiFiBio (Beijing) Biotechnology Co., Ltd. (referred to as HiFiBio) on September 9, 2024 in Beijing. The two parties plan to collaborate extensively in the field of innovative antibody drug research and development, focusing on unmet clinical needs, and exploring the research and production of innovative bispecific/multispecific antibodies based on disease mechanisms and target MOA. The two parties will follow market mechanisms and may engage in joint research projects, technology cooperation, and collaborative R&D.
Zhongguancun: Summary of the 2024 Semi-Annual Report
Zhongguancun: 2024 Semi-Annual Report
No Data
No Data